MedTrace Logo

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

NCT02227368 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-07-19

Study results available
· View outcomes & findings →

Summary

To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have undergone endovascular revascularization for moderate to severe claudication or ischemic rest pain.

Conditions

  • Peripheral Artery Disease (PAD)

Interventions

DRUG

Ticagrelor

Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.

DRUG

Comparator

Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures

Sponsors & Collaborators

  • CPC Clinical Research

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • William Hiatt, MD · Colorado Prevention Center Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-20
Primary Completion
2016-05-23
Completion
2016-05-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02227368 on ClinicalTrials.gov